Currently, there are 510.46M common shares owned by the public and among those 506.61M shares have been available to trade.
The company’s stock has a 5-day price change of 3.24% and -16.20% over the past three months. BAX shares are trading 5.01% year to date (YTD), with the 12-month market performance down to -23.53% lower. It has a 12-month low price of $28.33 and touched a high of $44.01 over the same period. BAX has an average intraday trading volume of 4.21 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.91%, -3.72%, and -13.85% respectively.
Institutional ownership of Baxter International Inc (NYSE: BAX) shares accounts for 93.98% of the company’s 510.46M shares outstanding.
It has a market capitalization of $15.63B and a beta (3y monthly) value of 0.59. The stock’s trailing 12-month PE ratio is 133.54, while the earnings-per-share (ttm) stands at $0.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.61% over the week and 2.45% over the month.
Analysts forecast that Baxter International Inc (BAX) will achieve an EPS of 0.52 for the current quarter, 0.49 for the next quarter and 2.48 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.51 while analysts give the company a high EPS estimate of 0.51. Comparatively, EPS for the current quarter was 0.88 a year ago. Earnings per share for the fiscal year are expected to decrease by -29.74%, and 35.23% over the next financial year.
Looking at the support for the BAX, a number of firms have released research notes about the stock. Morgan Stanley stated their Underweight rating for the stock in a research note on July 15, 2024, with the firm’s price target at $39-$30. Goldman coverage for the Baxter International Inc (BAX) stock in a research note released on May 30, 2024 offered a Neutral rating with a price target of $36. TD Cowen was of a view on May 10, 2024 that the stock is Hold, while Morgan Stanley gave the stock Equal-Weight rating on May 30, 2023, issuing a price target of $45. UBS on their part issued Neutral rating on March 29, 2023.
